How CRPC tumours develop resistance to enzalutamide remains to be fully understood, but it likely includes AR amplification, AR mutations, the generation of AR splice variants (AR-v), alterations to steroidogenesis, overexpression of glucocorticoid and progesterone receptors, and neuroendocrine differentiation [14,22,25]. This evidence concerns the gene AR and neoplasm.